Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company’s Board of Directors, effective immediately. In conjunction with Mr. Azelby’s appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service.

Read more at globenewswire.com